What Analysts Think about Ionis


Nov. 20 2020, Updated 4:28 p.m. ET

Analysts’ estimates

In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million. Analysts expect Ionis’s top line to rise ~30.2% to ~$135.7 million in the second quarter. The chart below shows analysts’ recommendations for Ionis stock over the last year.

Ionis’s stock price has fallen ~2.1% over the last 12 months and ~12.9% year-to-date. Analysts’ 12-month target price of $59.91 implies a ~36.8% return based on the stock’s May 22 price of $43.80.

Article continues below advertisement

Analysts’ recommendations

Of the 13 analysts tracking Ionis, one recommends “strong buy,” three recommend “buy,” seven recommend “hold,” one recommends “sell,” and one recommends “strong sell.” Their consensus rating for Ionis is 2.9, which represents a moderate “buy” for value investors. Analysts’ estimates and recommendations change based on companies’ stock prices and performance.

The First Trust NYSE Arca Biotechnology ETF (FBT) invests 2.9% of its portfolio in Ionis, 3.2% in Incyte (INCY), 3.4% in Biogen (BIIB), and 3.5% in bluebird bio (BLUE).

Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!


More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.